vimarsana.com
Home
Live Updates
FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat
FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat
FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer
Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.
Related Keywords
Matthew Powell ,
Hesham Abdullah ,
Tesaro Inc ,
,
Participants With Recurrent ,
Primary Advanced Endometrial Cancer ,
Gynecologic Oncology ,
Washington University School ,
Dostarlimab Combination ,
Primary Advanced ,
Recurrent Endometrial Cancer Pharmacy ,